Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 292

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 292
---
 
 labor or other compliance issues, environmental, intellectual property and title matters and compliance with various laws such as the     
 Foreign Corrupt Practices Act; and                                                                                                        |

| ● | covenants regarding matters such as no integration with other                                                                              
 offerings, filing of a Current Report on Form 8-K to disclose the consummation of the offering and entry in securities purchase agreements 
 and the placement agency agreement, no shareholder rights plans, no material nonpublic information, use of proceeds, indemnification,      
 reservation and listing of common stock.                                                                                                   |

Delivery of the shares of Common Stock, Pre-Funded Warrants and Offered Common Warrants offered hereby is expected to occur on or about , 2025, subject to satisfaction of certain customary closing conditions. Pursuant to a side letter between the placement agent and JonesTrading Institutional Services LLC (“Jones”), dated February 3, 2025, Jones agreed to be a financial advisor for the offering. In connection with the services provided by Jones, the placement agent and Jones agreed that the placement agent will receive an aggregate fee equal to 6% of the gross proceeds received in the offering and Jones will receive an aggregate fee equal to 3% of the gross proceeds received in the offering. In addition, we have agreed to reimburse the placement agent for its legal fees and expenses and other out-of-pocket expenses in an amount up to $85,000, non-accountable expenses of up to $25,000 and we have agreed to reimburse the financial advisor for all reasonable and documented out-of-pocket fees and expenses, including but not limited to travel and other out-of-pocket expenses in an amount not to exceed $15,000. We estimate the total expenses of this offering paid or payable by us, exclusive of the placement agent’s cash fee of 6% of the gross proceeds, the financial advisor’s cash fee of 3% of the gross proceeds and expenses of the placement agent and financial advisor, will be approximately $425,000. After deducting the fees due to the placement agent and our estimated expenses in connection with this offering, we expect the net proceeds from this offering will be approximately $6.9 million. The following table shows the per share and total cash fees we will pay to the placement agent and financial advisor in connection with the sale of the Common Stock, Pre-Funded Warrants, Offered Common Warrants and shares of Common Stock underlying the Pre-Funded Warrants and Offered Common Warrants pursuant to this prospectus.

|                                            |     |   |